drugset / Trial / NCT07852832

Effects of Psilocybin on Craving in Nicotine Dependence

NCT07852832 ↗

Phase 2 Not yet recruiting 3 enrolled University of British Columbia
NaSingle-groupOpen-labelBasic science

Summary

This pilot study will examine how a single 25 mg dose of psilocybin affects nicotine craving in people with nicotine dependence. Following psilocybin administration, participants will complete repeated brain imaging (MRI) sessions that mimic the design and procedures of the SCANS (H24-02776) study they previously completed. This will allow us to compare craving and related brain activity before and after psilocybin. We will also explore changes in nicotine use, thoughts about nicotine, motivation to quit, and mental health symptoms. Findings will help inform the design of larger future studies of psilocybin for substance use.

Timeline

Start
2027-01
Primary completion
2027-12
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 25 mg —

Indications